MDT

88.32

-0.47%↓

VEEV

281.13

+0.19%↑

A

119.05

-1.94%↓

WBA

11.56

+0.43%↑

HQY

101.32

-1.8%↓

MDT

88.32

-0.47%↓

VEEV

281.13

+0.19%↑

A

119.05

-1.94%↓

WBA

11.56

+0.43%↑

HQY

101.32

-1.8%↓

MDT

88.32

-0.47%↓

VEEV

281.13

+0.19%↑

A

119.05

-1.94%↓

WBA

11.56

+0.43%↑

HQY

101.32

-1.8%↓

MDT

88.32

-0.47%↓

VEEV

281.13

+0.19%↑

A

119.05

-1.94%↓

WBA

11.56

+0.43%↑

HQY

101.32

-1.8%↓

MDT

88.32

-0.47%↓

VEEV

281.13

+0.19%↑

A

119.05

-1.94%↓

WBA

11.56

+0.43%↑

HQY

101.32

-1.8%↓

Search

Ovid therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

0.42 16.67

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.36

Max

0.43

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-982K

-10M

Pardavimai

54K

130K

Pelnas, tenkantis vienai akcijai

-0.14

Pelno marža

-7,873.077

Darbuotojai

23

EBITDA

-1.8M

-12M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+664.86% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-12

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.4M

23M

Ankstesnė atidarymo kaina

-16.25

Ankstesnė uždarymo kaina

0.42

Naujienos nuotaikos

By Acuity

50%

50%

162 / 376 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Ovid therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-08 19:37; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

M3-Brigade Shares Fall on Merger With ReserveOne

2025-07-08 23:45; UTC

Rinkos pokalbiai

Gold Edges Lower, Weighed by Higher Treasury Yields -- Market Talk

2025-07-08 23:42; UTC

Rinkos pokalbiai

Nikkei May Rise as Yen Weakens -- Market Talk

2025-07-08 23:27; UTC

Rinkos pokalbiai

Australian REITs Yet to Offer Enough Appeal -- Market Talk

2025-07-08 23:27; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-08 23:21; UTC

Rinkos pokalbiai

Summerset Bull Lauds Strong 2Q Sales Volumes -- Market Talk

2025-07-08 23:21; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-07-08 22:29; UTC

Įsigijimai, susijungimai, perėmimai

Capricorn to Pay A$1.5 Million in Cash and Shares

2025-07-08 22:28; UTC

Įsigijimai, susijungimai, perėmimai

Capricorn Metals Enters Binding Agreement to Buy Claw Gold Project

2025-07-08 21:58; UTC

Rinkos pokalbiai

Kura Sushi Closely Watching U.S. Tariff Negotiations on Asian Goods -- Market Talk

2025-07-08 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-07-08 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-07-08 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-08 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-08 19:53; UTC

Rinkos pokalbiai

Copper Posts Biggest One-Day Gain Ever to Hit Record on Tariff Chatter -- Market Talk

2025-07-08 19:53; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-07-08 19:45; UTC

Rinkos pokalbiai

Canada Unlikely to Succeed in Bid for Tariff-Free Trade With U.S. -- Market Talk

2025-07-08 19:29; UTC

Rinkos pokalbiai

U.S. Consumer-Credit Growth Slowed in May -- Market Talk

2025-07-08 19:20; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Lower -- Market Talk

2025-07-08 19:11; UTC

Rinkos pokalbiai

Bank of Canada's Rate Cuts Deliver Muted Relief Along the Curve -- Market Talk

2025-07-08 19:01; UTC

Rinkos pokalbiai

Oil Futures Gain With Support From Products -- Market Talk

2025-07-08 18:49; UTC

Uždarbis

Hershey Names New CEO, Continuing Leadership Shuffle. The Stock Falls. -- Barrons.com

2025-07-08 18:41; UTC

Rinkos pokalbiai

Mexico's Inflation Seen Mixed in June -- Market Talk

2025-07-08 18:38; UTC

Rinkos pokalbiai

Gold Falls as Markets Digest Details of Trump Tariffs -- Market Talk

2025-07-08 18:23; UTC

Rinkos pokalbiai

Analysts Anticipate Lower Ethanol Inventories -- Market Talk

2025-07-08 18:10; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-07-08 18:10; UTC

Rinkos pokalbiai

Freeport-McMoRan Jumps on Trump Tariff Plan for Copper Imports -- Market Talk

2025-07-08 17:24; UTC

Rinkos pokalbiai

Election, Dollar Seen as Potential Headwinds for Ibovespa -- Market Talk

2025-07-08 17:06; UTC

Rinkos pokalbiai

KeyCorp and Regional Banks Set for a Catchup -- Market Talk

2025-07-08 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Ovid therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

664.86% į viršų

12 mėnesių prognozė

Vidutinis 2.83 USD  664.86%

Aukščiausias 4 USD

Žemiausias 1.5 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ovid therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

5

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

0.275 / 0.33Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

162 / 376 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.